Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: a randomized, double-blind, placebo-controlled pilot study
Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: a randomized, double-blind, placebo-controlled pilot study
Post author correction
Article Type: ORIGINAL ARTICLE
DOI:10.5301/jva.5000187
Authors
Haimanot Wasse, Rong Huang, Qi Long, Yize Zhao, Salman Singapuri, William McKinnon, George Skardasis, Vin Tangpricha
Corresponding author
- Haimanot Wasse
- Emory University School of Medicine
- Woodruff Memorial Research Building, Room 338 1639 Pierce Dr. Atlanta, GA 30322, USA
Abstract
Purpose: While vitamin D is critical for optimal skeletal health, it also appears to play a significant role in vascular homeostasis. This pilot study compared arteriovenous (AV) access outcomes following cholecalciferol supplementation compared to placebo in end-stage renal disease patients preparing to undergo AV access creation.
Methods: A total of 52 adult hemodialysis patients preparing for arteriovenous fistula (AVF) creation were randomized to receive perioperative high-dose cholecalciferol versus placebo in this double-blind, randomized, placebo-controlled pilot study. The primary outcome was mean response to high-dose oral cholecalciferol versus placebo, and secondary outcome AV access maturation at 6 months. Logistic regression was used to assess the association between AV access maturation and baseline, posttreatment and overall change in vitamin D concentration.
Results: A total of 45% of cholecalciferol-treated and 54% of placebo-treated patients were successfully using their AVF or arteriovenous graft (AVG) at 6 months (p=0.8). Baseline serum concentrations of 25(OH)D and 1,25(OH)2D did not differ between those who experienced AVF or AVG maturation and those who did not (p=0.22 and 0.59, respectively). Similarly, there was no relationship between AVF or AVG maturation and posttreatment serum 25(OH)D and 1,25(OH)2D concentration (p=0.24 and 0.51, respectively).
Conclusions: Perioperative high-dose vitamin D3 therapy does correct 25(OH)D level but does not appear to have an association with AV access maturation rates. Future research may include extended preoperative vitamin D3 therapy in a larger population or in certain subpopulations at high risk for AVF failure.
Article History
- • Accepted on 15/08/2013
- • Available online on 07/10/2013
Disclosures
Article usage statistics
The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.
Authors
- Wasse, Haimanot [PubMed] [Google Scholar] 1, * Corresponding Author
- Huang, Rong [PubMed] [Google Scholar] 1
- Long, Qi [PubMed] [Google Scholar] 2
- Zhao, Yize [PubMed] [Google Scholar] 2
- Singapuri, Salman [PubMed] [Google Scholar] 1
- McKinnon, William [PubMed] [Google Scholar] 3
- Skardasis, George [PubMed] [Google Scholar] 3
- Tangpricha, Vin [PubMed] [Google Scholar] 4
Affiliations
- Division of Nephrology, Emory University, Atlanta, GA - USA
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA - USA
- Peachtree Vascular Associates, Emory University Hospital Midtown, Atlanta, GA - USA
- Division of Endocrinology, Metabolism and Lipids, Emory University, Atlanta, GA - USA